{
    "root": "31576cda-7134-cc0b-e063-6294a90acef8",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ergotamine tartrate and caffeine",
    "value": "20250327",
    "ingredients": [
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "68401960MK"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FD&C YELLOW NO. 5",
            "code": "I753WB2F1M"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "ERGOTAMINE TARTRATE",
            "code": "MRU5XH3B48",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4827"
        },
        {
            "name": "CAFFEINE",
            "code": "3G6A5W338E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27732"
        }
    ],
    "indications": {
        "text": "ergotamine tartrate caffeine tablets indicated therapy abort prevent vascular headache ; e.g . , migraine , migraine variants so-called \u201c histaminic cephalalgia . \u201d",
        "doid_entities": [
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "procedure : best results , start first sign attack . adults : take 2 tablets start attack ; 1 additional tablet every \u00bd hour , needed full relief ( maximum 6 tablets per attack , 10 per week ) . maximum adult : total daily dose one attack exceed 6 tablets . total weekly exceed 10 tablets . ergotamine tartrate caffeine tablets used chronic daily . carefully selected patients , due consideration maximum recommendations , bedtime may appropriate short-term preventive measure .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ergotamine tartrate caffeine tablets , usp oral available : 1 mg/100 mg : beige ( film coated ) , round , convex face tablets , debossed \u201c 123 \u201d one side \u201c mh \u201d side . bottles 100. . . . . . ndc 24470-917-10 bottles 40 . . . . . . . ndc 24470-917-40 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ( usp controlled room temperature ) . dispense tight , light-resistant container . keep reach children . distributed cintex services , llc dallas , tx 75243 manufactured mikart , llc atlanta , ga 30318 code 1098c00 rev . 11/24",
    "adverseReactions": "coadministration ergotamine potent cyp 3a4 inhibitors ( ritonavir , nelfinavir , indinavir , erythromycin , clarithromycin , troleandomycin ) associated acute ergot toxicity ( ergotism ) characterized vasospasm ischemia extremities ( : ) , cases resulting amputation . rare reports cerebral ischemia patients protease inhibitor therapy ergotamine tartrate caffeine tablets coadministered , least one resulting death . increased risk ergotism serious vasospastic events , ergotamine contraindicated drugs potent inhibitors cyp 3a4 ( e.g . , ketoconazole , itraconazole ) ( : cyp 3a4 inhibitors ) . ergotamine tartrate caffeine tablets may cause fetal harm administered pregnant women . ergotamine tartrate caffeine tablets contraindicated women may become pregnant . used pregnancy patient becomes pregnant taking product , patient apprised potential hazard fetus . peripheral vascular disease , coronary heart disease , hypertension , impaired hepatic renal function sepsis . hypersensitivity components .",
    "indications_original": "Ergotamine tartrate and caffeine tablets are indicated as therapy to abort or prevent vascular headache; e.g., migraine, migraine variants or so-called \u201chistaminic cephalalgia.\u201d",
    "contraindications_original": "Procedure: For the best results, dosage should start at the first sign of an attack. Adults: Take 2 tablets at the start of attack; 1 additional tablet every \u00bd hour, if needed for full relief (maximum 6 tablets per attack, 10 per week).\n                  \n                     Maximum Adult Dosage:\n                  \n                  Total daily dose for any one attack should not exceed 6 tablets. Total weekly dosage should not exceed 10 tablets. Ergotamine tartrate and caffeine tablets should not be used for chronic daily administration. In carefully selected patients, with due consideration of maximum dosage recommendations, administration of the drug at bedtime may be an appropriate short-term preventive measure.",
    "warningsAndPrecautions_original": "Ergotamine tartrate and caffeine tablets, USP for oral administration are available as:\n                  \n                     1 mg/100 mg: beige (film coated), round, convex face tablets, debossed \u201c123\u201d on one side and \u201cMH\u201d on the other side.\n \n                  Bottles of 100......NDC 24470-917-10\n                  \n                  Bottles of 40 .......NDC 24470-917-40\n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) (see USP Controlled Room Temperature).\n                  Dispense in a tight, light-resistant container.\n                  \n                  \n                  \n                  \n                     KEEP OUT OF THE REACH OF CHILDREN.\n                  \n                  \n                  \n                  Distributed by\n                  \n                     Cintex Services, LLC\n                  \n                  Dallas, TX 75243\n                  \n                  \n                  \n                  \n                  Manufactured by\n                  \n                     MIKART, LLC\n                  \n                  Atlanta, GA 30318\n                  \n                  \n                  \n                  \n                  Code 1098C00\n                  Rev. 11/24",
    "adverseReactions_original": "Coadministration of ergotamine with potent CYP 3A4 inhibitors (ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, and troleandomycin) has been associated with acute ergot toxicity (ergotism) characterized by vasospasm and ischemia of the extremities (see \n  \n                        PRECAUTIONS: \n   Drug Interactions\n                     ), with some cases resulting in amputation. There have been rare reports of cerebral ischemia in patients on protease inhibitor therapy when ergotamine tartrate and caffeine tablets was coadministered, at least one resulting in death. Because of the increased risk of ergotism and other serious vasospastic adverse events, ergotamine use is contraindicated with these drugs and other potent inhibitors of CYP 3A4 (e.g., ketoconazole, itraconazole) (see \n  \n                        WARNINGS: \n   CYP 3A4 Inhibitors\n                     ).\n \n                  Ergotamine tartrate and caffeine tablets may cause fetal harm when administered to pregnant women. Ergotamine tartrate and caffeine tablets is contraindicated in women who are or may become pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this product, the patient should be apprised of the potential hazard to the fetus.\n                  Peripheral vascular disease, coronary heart disease, hypertension, impaired hepatic or renal function and sepsis.\n                  Hypersensitivity to any of the components.",
    "drug": [
        {
            "name": "ergotamine tartrate and caffeine",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64318"
        }
    ]
}